Yesterday I saw a stock market segment on the Internet: In 2022, how come you don't have any money? Answer: Did not control their hands, chased the demon stocks; too confident that it will rebound, heavy positions in the mainstream track stocks, the result is "endless fall".
Since the beginning of 2022, many of the former demon stocks have been extinguished, and the former popular track medicine and new energy have continued to pull back, allowing the high-chasers and heavy warehouses to eat a large bowl of cold noodles.
Since the second half of last year, the CXO sector of innovative drugs has shown several rounds of crazy roller coasters, entering 2022, and it is still "falling endlessly". The leading stock Kaleiying stock price has hit a new recent low, and the stock price has been cut compared with the high price on November 30, 2021.
Last year, the demon stock stained with the "sauce fragrant liquor concept" - Zhongrui shares have also been cut off, so that the chasers feel what is the "mountain top frozen man".
Some investors said, "I've lost a lot of money!" It is difficult to make money in 2021, but I did not expect that 2022 will be even more difficult! ”
Gloria Ying slashed, and the market value of 70 billion yuan was gone
On February 11, the innovative drug CXO leader Kai Lai Ying fell again, setting a record of 8 consecutive yin, and the intraday stock price once hit a recent new low of 262.52 yuan / share.
As of the noon break, Gloria Ying fell 4.70%, the stock price was reported at 263.13 yuan / share, the latest total market value of 69.56 billion yuan.
K-line chart data show that on November 30, 2021, The stock price of Gloria Ying once hit a record high price of 532.49 yuan / share, and the total market value once reached 140.5 billion yuan, while the lowest price on February 11, 2022 compared with the high price, the stock price of Gloria Ying has been cut, and the total market value has evaporated by 70.9 billion yuan.
GloriaIn is a leading enterprise in the field of CXO small and medium-sized molecule CDMO. From 2018 to 2020, the CDMO industry has a high degree of prosperity, and the average annual revenue compound growth rate of the industry exceeds 40%. Benefiting from the prosperity of the industry, The performance of Clareying has also grown steadily.
From 2018 to 2020, the net profit growth rate of Gloria Ying was 25.49%, 29.32% and 30.37% respectively.
The steady growth of the industry boom and performance has promoted the continuous rise of the stock price of the secondary market of Gloria Ying and continued to reach new highs.
However, starting in December 2021, Gloria Ying's stock price began to pull back sharply. There are two possible reasons:
On the one hand, it is related to the CXO industry news, and the overall sector is falling sharply. In early July 2021, the document "Guidelines for Clinical Research and Development of Clinically Value-Oriented Antineoplastic Drugs" was released. Some people believe that if the above new policies are to be implemented, it will increase the research and development costs of pharmaceutical companies to a certain extent, and some pharmaceutical companies may reduce research and development, thus affecting the acceptance of orders by downstream CRO companies.
On the other hand, in the second half of 2021, the supervision of industries such as medical aesthetics and medical services has become stricter, making CXO a hot spot in the pharmaceutical industry, and many pharmaceutical theme funds and institutions have accelerated the purchase of CXO industry, which has promoted the continuous rise of CXO concept stock prices.
After the stock price rose to a high point, institutional and pharmaceutical theme funds began to choose to sell the bag for safety. For example, Hillhouse Capital once repositioned Gloria Ying in the second quarter of 2021 and became the top ten circulating shareholders, while in the third quarter, Hillhouse reduced its holdings in a large way and has withdrawn from the ranks of the top ten circulating shareholders.
Yesterday, the market spread the news that the fund managed by the top 100 billion Gülen suffered a large-scale redemption, and the fund managed by Gülen was a heavy position in pharmaceutical stocks such as Gloria Ying.
Although the celebrus fund responded later that the news was untrue, it brought panic to the market to a certain extent.
In the scale of Gloria Ying shareholder group, some investors said, "Brothers, I have more than 300 costs, see the price of Gloria Ying today, the mood is very bad!" ”。
What do you think about the 100 billion giant Gloria Ying waist chop?
Waist chop! 3 times the demon stock "Xiao Maotai" also collapsed
Investors who are heavily involved in pharmaceutical stocks are very uncomfortable, and investors who chase high demon stocks are also very uncomfortable.
On February 11, Zhongrui shares opened low and went low, and the stock price fell sharply. As of the noon break, the stock price of Zhongrui shares fell by 6.46%, and the latest stock price was 5.79 yuan per share, and the latest total market value was 6.299 billion yuan.
The main business of Zhongrui Co., Ltd. is the production, sales and related business of aluminum plate composite anti-counterfeiting printing and anti-counterfeiting caps, and it is known as the "first share of bottle caps" in the A-share market.
On November 27, 2021, Guiyan Bottle Liquor Company under Zhongrui Co., Ltd. was established. Shu Guohua, president of Guiyan bottle liquor industry, once said that it will take the high-quality sauce-flavored liquor in the core production area as the starting point to carry out the operation business of the liquor industry.
Due to the "sauce fragrant liquor", the stock price of Zhongrui shares has opened a soaring mode. From November 25, 2021 to January 5, 2022, in 29 trading days, Zhongrui shares rose and stopped 17 times. The stock price rose from a high of 2.79 yuan to 12.95 yuan, and the stock price rose by 364%, becoming a demon stock in the market. In the hearts of shareholders, Zhongrui shares also have the name of "Xiaomaotai".
However, since 2022, the stock price of Zhongrui shares has opened a sharp decline mode. As of the date of the document, the stock price of Zhongrui Shares in 2022 has fallen by 51%, and the stock price has been cut. Investors who are chasing high-tech shares have eaten a big bowl of cold noodles in 2022.
From the perspective of the market, the market's funds have no longer speculated on Zhongrui shares, and Zhongrui shares have not been on the Dragon and Tiger list for a long time, losing the attention of market funds, and the stock price of Zhongrui shares has also fallen.
In addition, in terms of performance, Zhongrui shares have serious losses. According to the 2021 performance forecast, in 2021, Zhongrui is expected to lose 550 million yuan to 650 million yuan in net profit, second only to the loss of 790 million yuan in 2018, and the net profit has been a significant loss for two consecutive years.
With a sharp loss in performance and a lack of market capital attention, the "small Moutai" that rubbed on the "sauce fragrant liquor" will not become Moutai after all, and the stock price has fallen sharply.
In the scale of the sharp stock shareholder group, some investors said, "Really think of themselves as Maotai, no performance, only rely on the concept of rubbing, sooner or later will play smash." Some investors said, "No longer chase these demon stocks, 12 yuan of this, bought a big set for yourself." ”
What do you think about Zhongrui shares?